Allergan Catalysts Drive Expansion and 4 Stock Analyses to Know Now
Allergan Inc. (NYSE:AGN): Current price $42.45
After rolling their valuation out to 2014, Susquehanna raised their price target for Allergan Inc. shares and keeps an Outperform rating on the name. Susquehanna expects Allergan to be a much better performer in 2013 after underperforming the specialty pharma group in 2012. The firm believes that pipeline catalysts could support multiple expansion in 2013.
Celldex Therapeutics, Inc. (NASDAQ:CLDX):Current price $7.54
Cantor expects the visibility of Celldex Therapeutics, Inc.’s pipeline to increase this year, mitigating the stock’s risk. The firm maintains a Buy rating on the shares.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.
ON Semiconductor Corp. (NASDAQ:ONNN): Current price $7.5650
After meeting with ON Semiconductor Corp.’s Chief Financial Officer, Stifel Nicolaus thinks the company’s operating margins can increase in 2013 and the firm believes that the margins will get a boost from the weak yen. Stifel raised their price target on the stock from $7.50 to $9 and maintains a Buy rating.
Las Vegas Sands Corp. (NYSE:LVS): Current price $51.80
Lazard Capital raised their estimates and price target for Las Vegas Sands Corp. citing a higher assumed market growth in Macau, and keeps a Buy rating on the stock.
Open Text Corp. (NASDAQ:OTEX): Current price $58.63
RBC Capital believes that Open Text Corp.’s sales force expansion increases the chances that their growth will accelerate in 2013. The firm thinks the company’s second quarter results could beat expectations and they maintain an Outperform rating.
Investing Insights: Does Apollo Group’s Big Drop Present a Buying Opportunity?